Stock ACAD ACADIA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus ACADIA Pharmaceuticals Inc.

Equities

ACAD

US0042251084

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-18 pm EDT 		5-day change 1st Jan Change
17.07 USD -0.70% Intraday chart for ACADIA Pharmaceuticals Inc. -1.95% -45.48%
Apr. 17 ACADIA Pharmaceuticals Inc. Presents New DAYBUE (trofinetide) Clinical Data at the 2024 American Academy of Neurology Annual Meeting CI
Apr. 02 ACADIA Pharmaceuticals Inc. Appoints Elizabeth H. Z. Thompson, Ph.D. as Executive Vice President, Head of Research and Development CI

Evolution of the average Target Price on ACADIA Pharmaceuticals Inc.

Price target over the last 5 years

History of analyst recommendation changes

d565a0458fbdae40add539d845f5f.fLpajh7OShMh0FDWTZCRG_EXakesmrU5UK7NaPJdBe8.T8o2906_LmcXij6lH9HJKIQuWAHv78NdM8e5G4M_Q9dE8z3CM4gufmSFNw~3d4fc695f1e911df7adba7231215541d

Analyst Recommendations on ACADIA Pharmaceuticals Inc.

JPMorgan Adjusts Price Target on ACADIA Pharmaceuticals to $25 From $29, Maintains Overweight Rating MT
UBS Adjusts ACADIA Pharmaceuticals Price Target to $33 From $35, Maintains Buy Rating MT
Morgan Stanley Cuts Price Target on ACADIA Pharmaceuticals to $30 From $40 After Failed Study of Pimavanserin in Negative Symptoms of Schizophrenia; Overweight Kept MT
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $22 From $24, Maintains Hold Rating MT
Cantor Fitzgerald Adjusts Price Target on ACADIA Pharmaceuticals to $37 From $42, Maintains Overweight Rating MT
Baird Adjusts Price Target on ACADIA Pharmaceuticals to $31 From $40, Maintains Outperform Rating MT
Needham Lowers Price Target on ACADIA Pharmaceuticals to $32 From $36, Keeps Buy Rating MT
Oppenheimer Adjusts ACADIA Pharmaceuticals Price Target to $19 From $25, Maintains Perform Rating MT
Canaccord Genuity Adjusts Price Target on ACADIA Pharmaceuticals to $33 From $40, Keeps Buy Rating MT
JMP Securities Cuts ACADIA Pharmaceuticals Price Target to $39 From $44, Maintains Market Outperform Rating MT
RBC Cuts Price Target on ACADIA Pharmaceuticals to $30 From $35 After Phase 3 Trial of Pimavanserin Fails to Reach Primary Endpoint; Outperform Kept MT
Mizuho Securities Downgrades ACADIA Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $25 From $39 MT
JPMorgan Cuts Price Target on ACADIA Pharmaceuticals to $29 From $32, Maintains Overweight Rating MT
Deutsche Bank Trims ACADIA Pharmaceuticals Price Target to $24 From $25, Maintains Hold Rating MT
Needham Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Maintains Buy Rating MT
Mizuho Securities Adjusts Price Target on ACADIA Pharmaceuticals to $39 From $40, Maintains Buy Rating MT
RBC Trims Price Target on ACADIA Pharmaceuticals to $35 From $36, Keeps Outperform Rating MT
Baird Initiates ACADIA Pharmaceuticals With Outperform Rating, Price Target is $40 MT
Needham Upgrades ACADIA Pharmaceuticals to Buy From Hold, Price Target is $37 MT
RBC Boosts Price Target on ACADIA Pharmaceuticals to $36 From $33, Keeps Outperform Rating MT
Mizuho Securities Boosts Price Target on ACADIA Pharmaceuticals to $40 From $35, Keeps Buy Rating MT
Morgan Stanley Upgrades ACADIA Pharmaceuticals to Overweight From Equalweight, Raises Price Target to $40 From $31 MT
Stifel Adjusts Price Target on ACADIA Pharmaceuticals to $27 From $25, Maintains Hold Rating MT
Deutsche Bank Downgrades ACADIA Pharmaceuticals to Hold From Buy, Retains $25 PT; Says Reaction to Favorable Summary Judgement on Pimavanserin's ANDA Litigation 'Slightly Overdone' MT
Deutsche Bank Initiates Coverage on ACADIA Pharmaceuticals With Buy Rating, $25 Price Target MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
17.07 USD
Average target price
29.17 USD
Spread / Average Target
+70.87%
High Price Target
39 USD
Spread / Highest target
+128.47%
Low Price Target
13 USD
Spread / Lowest Target
-23.84%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ACADIA Pharmaceuticals Inc.

JPMorgan Chase
UBS
Morgan Stanley
Deutsche Bank Securities
Cantor Fitzgerald
Baird
Needham & Co.
Oppenheimer
Canaccord Genuity
JMP Securities
RBC Capital Markets
Mizuho Securities
Stifel Nicolaus
Citigroup
HC Wainwright
BofA Securities
Guggenheim
Goldman Sachs
Loop Capital
SVB Securities LLC
Cowen
Jefferies & Co.
Berenberg Bank
SMBC Nikko
SVB Leerink
Raymond James

Ratings for ACADIA Pharmaceuticals Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ACAD Stock
  4. Consensus ACADIA Pharmaceuticals Inc.